Psagot Value Holdings’s BioLineRX BLRX Stock Holding History

Psagot Value Holdings’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,925	Closed	-$326K	–	438
2021 Q1	$326K	Hold	2,925	–	–	0.01%	249
2020 Q4	$295K	Hold	2,925	–	–	0.01%	232
2020 Q3	$192K	Hold	2,925	–	–	﹤0.01%	265
2020 Q2	$200K	Buy	+2,925	New	+$200K	0.01%	241
2019 Q4	–	Sell	-6	Closed	-$1K	–	430
2019 Q3	$1K	Buy	+6	New	+$832	﹤0.01%	388
2019 Q2	–	Sell	-11	Closed	-$3K	–	410
2019 Q1	$3K	Hold	11	–	–	﹤0.01%	430
2018 Q4	$3K	Buy	11 +3	+38%	+$1.44K	﹤0.01%	428
2018 Q3	$5K	Sell	8 -1	-11%	-$550	﹤0.01%	351
2018 Q2	$5K	Buy	9 +1	+13%	+$531	﹤0.01%	323
2018 Q1	$4K	Sell	8 -1	-11%	-$613	﹤0.01%	324
2017 Q4	$6K	Sell	9 -8	-47%	-$5.27K	﹤0.01%	283
2017 Q3	$12K	Sell	17 -166	-91%	-$103K	﹤0.01%	291
2017 Q2	$93K	Buy	+183	New	+$94.1K	﹤0.01%	232

Other funds holding BLRX

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

GPFA

Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Psagot Value Holdings's BLRX Position: Q2 2021 in Review

Psagot Value Holdings sold out of BioLineRX (BLRX) in Q2 2021, closing a stake of 2,925 shares — an estimated $326K sold.

Psagot Value Holdings first reported a position in BLRX in Q2 2017 and held it in 13 quarters. The position peaked at $326K in Q1 2021. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2021.

Psagot Value Holdings reported no remaining BioLineRX position as of Q2 2021 after selling out during the quarter.
Psagot Value Holdings sold 2,925 BioLineRX shares in Q2 2021, an estimated $326K.
Psagot Value Holdings first reported a position in BioLineRX in Q2 2017 and held it in 13 quarters.
Psagot Value Holdings's BioLineRX position peaked at $326K in Q1 2021.
28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2021.

Based on Psagot Value Holdings's 13F filing for Q2 2021, filed 11 Aug 2021.